You are here

Results of Phase 3 ABRAXANE® Combination Trial In First-Line Non-Small Cell Lung Cancer Show 31 Percent Improvement In Response Rate Compared With Taxol Combination

Results of Phase 3 ABRAXANE® Combination Trial In First-Line Non-Small Cell Lung Cancer Show 31 Percent Improvement In Response Rate Compared With Taxol Combination

Submitted by admin on June 5, 2010 - 12:34pm

Source:

BusinessWire

News Tags:

non-small cell lung cancer

Headline:

Results of Phase 3 ABRAXANE® Combination Trial In First-Line Non-Small Cell Lung Cancer Show 31 Percent Improvement In Response Rate Compared With Taxol Combination